NCT01364064已完成3 期
Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,153
- 主要终点
- safety and efficacy
研究概览
简要总结
This is a Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma.
详细描述
Primary objective is to determine if dose-intensifying (increasing the "dose-density") the adjuvant temozolomide component of the chemoradiation treatment enhances treatment efficacy as measured by overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Karnofsky performance status of ≥
- •Age ≥ 18 years.
- •CBC/differential obtained within 14 days prior to study registration, with adequate bone marrow function as defined below:
- •Absolute neutrophil count (ANC) ≥ 1500 cells/mm
- •Platelets ≥ 100,000 cells/mm
- •Hemoglobin ≥ 10 g/dl. (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)
- •Adequate renal function, as defined below:
- •BUN ≤ 25 mg/dl within 14 days prior to study registration
- •Creatinine ≤ 1.7 mg/dl within 14 days prior to study registration
- •Adequate hepatic function, as defined below:
- •Bilirubin ≤ 2.0 mg/dl within 14 days prior to study registration
- •ALT ≤ 3 x normal range within 14 days prior to study registration
- •AST ≤ 3 x normal range within 14 days prior to study registration
- •Patients must sign a study-specific informed consent prior to study registration.
- •If the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the responsible family member.
- •For females of child-bearing potential, negative serum pregnancy test within 72 hours prior to starting temozolomide.
- •Women of childbearing potential and male participants must practice adequate contraception.
排除标准
- •Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years. (For example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible).
- •Recurrent or multifocal malignant gliomas
- •Metastases detected below the tentorium or beyond the cranial vault.
- •Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable. Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted.
- •Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields.
- •Severe, active co-morbidity, defined as follows:
- •Unstable angina and/or congestive heart failure requiring hospitalization
- •Transmural myocardial infarction within the last 6 months
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- •Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.
- •Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
- •Major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.
- •Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
研究组 & 干预措施
Conventional adjuvant Temozolomide
Active Comparator
TMZ d 1-5 of 28-d cycle 6 cycles
干预措施: TMZ (Drug)
Dose intensive Temozolomide
Experimental
TMZ d 1-21 of 28-d cycle 6 cycles
干预措施: TMZ (Drug)
结局指标
主要结局
safety and efficacy
时间窗: 5 years
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.anaplastic gliomaMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-001533-17-NLEORTC European Organisation for research and treatment of cancer751
进行中（未招募）
1 期
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.EUCTR2006-001533-17-FREORTC European Organisation for research and treatment of cancer748
进行中（未招募）
1 期
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.anaplastic gliomaMedDRA version: 9.1 Level: LLT Classification code 10018337 Term: Glioblastoma multiformeEUCTR2006-001533-17-ESEORTC European Organisation for research and treatment of cancer748
进行中（未招募）
不适用
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.EUCTR2006-001533-17-GBEORTC European Organisation for research and treatment of cancer748
进行中（未招募）
1 期
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.anaplastic gliomaMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-001533-17-BEEORTC748